Synthetic Blood International to File Phase II-B Brain Injury Trial Protocol
Posted on: Tuesday, 8 April 2008, 12:01 CDT
Synthetic Blood International has announced that it intends to file a clinical protocol in mid-April, 2008, with the FDA for its planned Phase II-b clinical trial of Oxycyte in traumatic brain injury patients. Oxycyte is the company's perfluorocarbon therapeutic oxygen carrier and blood substitute.
The decision to file the protocol was made after the FDA accepted without comment the report on the results of the traumatic brain injury (TBI) Phase II-a safety study.
The company's planned multi-center, double-bind, placebo-controlled study would enroll up to 300 patients. Approximately 200 patients will be allowed for enrollment through a recently approved $1.9 million grant from the US Department of Defense to Ross Bullock, of the University of Miami Miller School of Medicine, department of Neurosurgery. Dr Bullock is the principal investigator for the planned Phase II-b clinical trial. The company plans to do an interim analysis after enrolling 100 patients and then may elect to enroll up to 300.
Source: Datamonitor
Related Articles
- Aerovance Completes Patient Enrollment in Phase 2b Clinical Trial of Aerovant(TM) for Treatment of Uncontrolled Asthma
- Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
- ERYtech Pharma Enrolled Its Last Patient for Its Phase II GRASPALL Clinical Trial and Selects Philadelphia Science Center As US Headquarters
- Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug
- Affymax Doses First Patient in the Phase 3 Clinical Program of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
- Sciele Completes Enrollment of Patients in Pivotal Phase III Clinical Trial for the Combination of Pravastatin and Fenofibrate
- Sciele Begins to Enroll Patients in a Pivotal Phase III Clinical Trial for the Combination of Pravastatin and Fenofibrate
- Critical Therapeutics Completes Dosing of First Patient in Clinical Trial of Intravenous Zileuton
- Sangamo BioSciences Announces Plans for Phase 2 Clinical Trial of ZFP Therapeutic in Diabetic Neuropathy at JPMorgan Healthcare Conference
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds